Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Merus N.V. CS (MRUS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 310,779
  • Shares Outstanding, K 22,751
  • Annual Sales, $ 37,140 K
  • Annual Income, $ -28,660 K
  • 60-Month Beta -0.05
  • Price/Sales 8.31
  • Price/Cash Flow N/A
  • Price/Book 2.84

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.52
  • Number of Estimates 2
  • High Estimate -0.47
  • Low Estimate -0.57
  • Prior Year -0.49
  • Growth Rate Est. (year over year) -6.12%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.50 +9.20%
on 05/06/19
17.60 -22.44%
on 04/23/19
-3.18 (-18.89%)
since 04/22/19
3-Month
11.00 +24.09%
on 02/26/19
17.99 -24.12%
on 04/22/19
+2.56 (+23.08%)
since 02/22/19
52-Week
11.00 +24.09%
on 02/26/19
26.74 -48.95%
on 07/10/18
-4.83 (-26.14%)
since 05/22/18

Most Recent Stories

More News
Merus to Present at the RBC Capital Markets 2019 Healthcare Conference

UTRECHT, Netherlands, May 20, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) ("Merus", "we", "our" or the "Company"), a clinical-stage immuno-oncology company developing Biclonics(R), innovative...

MRUS : 13.65 (-0.07%)
Agios' Tibsovo Meets Endpoint in Cholangiocarcinoma Study

Agios' (AGIO) Tibsovo achieves the primary goal in a late-stage development that examined it for the previously treated IDH1 mutant cholangiocarcinoma. Shares rise in after-hours trading.

AGIO : 50.91 (-0.88%)
CELG : 95.89 (-0.37%)
MRUS : 13.65 (-0.07%)
GILD : 65.77 (-1.13%)
Mallinckrodt Ends Enrollment in Phase III for Terlipressin

Mallinckrodt (MNK) concludes enrollment in the phase III study on terlipressin, currently under development for treating adult patients with Hepatorenal Syndrome Type 1.

MRUS : 13.65 (-0.07%)
RGEN : 68.54 (-0.58%)
GILD : 65.77 (-1.13%)
MNK : 9.53 (-3.44%)
Tilray (TLRY) to Report Q1 Earnings: What's in the Cards?

Investors will focus on pipeline progress and updates, when Tilray (TLRY) reports first-quarter 2019 results.

ADVM : 9.24 (-0.54%)
MRUS : 13.65 (-0.07%)
TLRY : 46.77 (+4.91%)
NVS : 83.13 (+0.90%)
Tilray (TLRY) to Report Q1 Earnings: What's in the Cards?

Investors will focus on pipeline progress and updates, when Tilray (TLRY) reports first-quarter 2019 results.

ADVM : 9.24 (-0.54%)
MRUS : 13.65 (-0.07%)
TLRY : 46.77 (+4.91%)
NVS : 83.13 (+0.90%)
Merus Announces First Patient Treated in Phase 1 Clinical Trial of MCLA-145 for Advanced Solid Tumors

UTRECHT, Netherlands, May 09, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage immuno-oncology company developing Biclonics(R), innovative full-length human bispecific antibody therapeutics,...

MRUS : 13.65 (-0.07%)
INCY : 78.19 (-0.62%)
Evoke Pharma (EVOK) to Post Q1 Earnings: What's in Store?

During Evoke Pharma's (EVOK) Q1 conference call, investor focus will be on its progress and issues related to the NDA submission for Gimoti to treat diabetic gastroparesis.

ADVM : 9.24 (-0.54%)
MRUS : 13.65 (-0.07%)
RGEN : 68.54 (-0.58%)
EVOK : 0.60 (unch)
Agios (AGIO) Earnings and Revenues Surpass Estimates in Q1

Agios (AGIO) benefits from earnings as well as revenue beat in first-quarter 2019. However, Tibsovo sales fall sequentially, pulling the stock down.

AGIO : 50.91 (-0.88%)
CELG : 95.89 (-0.37%)
PDLI : 3.02 (-0.66%)
MRUS : 13.65 (-0.07%)
Factors of Influence in 2019, Key Indicators and Opportunity within Jianpu Technology, Merus N.V., Xunlei, and The KEYW Holding -- New Research Emphasizes Economic Growth

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Jianpu Technology Inc. (NYSE:JT),...

MRUS : 13.65 (-0.07%)
JT : 4.95 (+1.02%)
KEYW : 11.26 (unch)
XNET : 2.68 (-6.29%)
Acorda (ACOR) Earnings and Revenues Beat Estimates in Q1

Acorda's (ACOR) shares rise on earnings and revenue beat in Q1. Inbrija registers first sales figure following its launch in the reported quarter.

MYL : 19.53 (-0.71%)
PDLI : 3.02 (-0.66%)
MRUS : 13.65 (-0.07%)
ACOR : 10.78 (-1.37%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade MRUS with:

Business Summary

Merus B.V. is a clinical-stage immuno-oncology company developing bispecific antibody therapeutics, referred to as Biclonics. The company's bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial as a potential treatment for HER2-expressing solid tumors; MCLA-117, is...

See More

Key Turning Points

2nd Resistance Point 14.39
1st Resistance Point 14.02
Last Price 13.65
1st Support Level 13.27
2nd Support Level 12.89

See More

52-Week High 26.74
Fibonacci 61.8% 20.73
Fibonacci 50% 18.87
Fibonacci 38.2% 17.01
Last Price 13.65
52-Week Low 11.00

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar